Axa
PLRX icon

Axa’s Pliant Therapeutics PLRX Stock Holding History

Axa’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-346,941
Closed -$4.57M – 1121
2024
Q4 		$4.57M Sell
346,941
-546
-0.2% -$7.46K 0.01% 561
2024
Q3 		$3.9M Buy
347,487
+98
+0% +$1.23K 0.01% 609
2024
Q2 		$3.73M Buy
347,389
+195
+0.1% +$2.51K 0.01% 607
2024
Q1 		$5.17M Buy
347,194
+94
+0% +$1.55K 0.02% 551
2023
Q4 		$6.29M Sell
347,100
-8,397
-2% -$128K 0.02% 498
2023
Q3 		$6.16M Buy
355,497
+99,218
+39% +$1.72M 0.02% 491
2023
Q2 		$4.64M Buy
256,279
+17,731
+7% +$420K 0.02% 568
2023
Q1 		$6.35M Sell
238,548
-33,855
-12% -$964K 0.02% 509
2022
Q4 		$5.27M Sell
272,403
-25,995
-9% -$543K 0.02% 583
2022
Q3 		$6.23M Sell
298,398
-37,600
-11% -$719K 0.02% 532
2022
Q2 		$2.69M Buy
335,998
+966
+0.3% +$6.18K 0.01% 723
2022
Q1 		$2.35M Buy
+335,032
New +$3.42M 0.01% 802

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Axa's PLRX Position: Q1 2025 in Review

Axa sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 346,941 shares — an estimated $4.57M sold.

Axa first reported a position in PLRX in Q1 2022 and held it in 12 quarters. The position peaked at $6.35M in Q1 2023. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Axa reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Axa sold 346,941 Pliant Therapeutics shares in Q1 2025, an estimated $4.57M.
  • Axa first reported a position in Pliant Therapeutics in Q1 2022 and held it in 12 quarters.
  • Axa's Pliant Therapeutics position peaked at $6.35M in Q1 2023.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Axa's 13F filing for Q1 2025, filed 15 May 2025.